Drug Profile
Research programme: retinoic acid receptor gamma agonists - Lycera
Alternative Names: LYC 54143; RORgamma agonist - Lycera; RORγ agonists - LyceraLatest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Lycera
- Class Antineoplastics; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists; Retinoic acid receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Colorectal cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 28 Dec 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Cancer in USA (PO)